Found: 23
Select item for more details and to access through your institution.
In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1427424
- By:
- Publication type:
- Article
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-67906-w
- By:
- Publication type:
- Article
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01096-6
- By:
- Publication type:
- Article
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1123029
- By:
- Publication type:
- Article
Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 24, p. 15691, doi. 10.3390/ijms232415691
- By:
- Publication type:
- Article
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 188, doi. 10.3390/cancers14010188
- By:
- Publication type:
- Article
OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S34, doi. 10.1016/S2152-2650(21)02127-3
- By:
- Publication type:
- Article
P-065: CyTOF and single cell RNA sequencing reveal altered T cell phenotypes in Multiple Myeloma patients: implications for immunotherapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S74, doi. 10.1016/S2152-2650(21)02199-6
- By:
- Publication type:
- Article
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 293, doi. 10.1002/hon.2864
- By:
- Publication type:
- Article
Application of the Euro Clonality next‐generation sequencing‐based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 2, p. 378, doi. 10.1111/bjh.17519
- By:
- Publication type:
- Article
MYD88 L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation.
- Published in:
- Diagnostics (2075-4418), 2021, v. 11, n. 5, p. 779, doi. 10.3390/diagnostics11050779
- By:
- Publication type:
- Article
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 2, p. 437, doi. 10.1007/s00277-020-04384-w
- By:
- Publication type:
- Article
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
- Published in:
- Hematological Oncology, 2020, v. 38, n. 5, p. 698, doi. 10.1002/hon.2792
- By:
- Publication type:
- Article
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00189
- By:
- Publication type:
- Article
Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e13, doi. 10.1016/j.clml.2019.09.019
- By:
- Publication type:
- Article
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00528
- By:
- Publication type:
- Article
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow‐up.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 5, p. 693, doi. 10.1111/bjh.14681
- By:
- Publication type:
- Article
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data.
- Published in:
- BMC Bioinformatics, 2017, v. 18, p. 1, doi. 10.1186/s12859-017-1923-2
- By:
- Publication type:
- Article
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance
- Published in:
- Hematological Oncology, 2014, v. 32, n. 3, p. 133, doi. 10.1002/hon.2095
- By:
- Publication type:
- Article
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
- Published in:
- Annals of Hematology, 2013, v. 92, n. 11, p. 1503, doi. 10.1007/s00277-013-1797-y
- By:
- Publication type:
- Article
Telomeres and telomerase in normal and malignant B-cells.
- Published in:
- Hematological Oncology, 2010, v. 28, n. 4, p. 157, doi. 10.1002/hon.937
- By:
- Publication type:
- Article